Compare Global E Online Ltd (GLBE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Global E Online Ltd trades at $40.15 (market cap $6.75B), while State Street SPDR S&P Biotech ETF trades at $150.49 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Global E Online Ltd is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GLBE | XBI | |
|---|---|---|
Market Cap | $6.75B | $10.11B |
Volume | 1,468,708 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $42.36 | $169.55 |
52-Week Low | $27.54 | $104.99 |
Typical Hold Time | 21 Days | 37 Days |
Enterprise Value | $6.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year in Q2, with an adjusted EBITDA margin expansion to 20.9%. Analyst consensus is strongly bullish with a $48.86 price target, though recent insider selling and a high P/E ratio of 45.65 warrant attention.
The outlook for GLBE is positive based on robust revenue growth and raised guidance, but risks include high valuation multiples and insider selling activity. The stock presents a growth opportunity if execution continues, yet investors should weigh the premium valuation against future earnings potential amid competitive e-commerce markets.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
